MAPT and Alzheimer disease: While molecular imaging of amyloid, tau cascades and other targets has made significant progress in therapeutic trials by targeting the underlying pathology of AD, there have been no such studies reported on imaging neuropathological correlates of neuropsychiatric symptoms of AD.